Darden Restaurants, Inc. (DRI) Analysts See $1.64 EPS; NeoGenomics, Inc. (NEO) Covered By 9 Bulls

February 21, 2018 - By Migdalia James

Analysts expect Darden Restaurants, Inc. (NYSE:DRI) to report $1.64 EPS on March, 26.They anticipate $0.32 EPS change or 24.24% from last quarter’s $1.32 EPS. DRI’s profit would be $202.60 million giving it 14.61 P/E if the $1.64 EPS is correct. After having $0.73 EPS previously, Darden Restaurants, Inc.’s analysts see 124.66% EPS growth. The stock increased 1.01% or $0.96 during the last trading session, reaching $95.86. About 297,380 shares traded. Darden Restaurants, Inc. (NYSE:DRI) has risen 31.96% since February 21, 2017 and is uptrending. It has outperformed by 15.26% the S&P500.

Among 11 analysts covering NeoGenomics (NASDAQ:NEO), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. NeoGenomics had 17 analyst reports since September 3, 2015 according to SRatingsIntel. Roth Capital maintained the shares of NEO in report on Thursday, September 3 with “Buy” rating. The company was downgraded on Monday, September 11 by BTIG Research. The stock has “Neutral” rating by BTIG Research on Wednesday, July 27. William Blair maintained the shares of NEO in report on Sunday, September 6 with “Outperform” rating. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Overweight” rating by First Analysis on Tuesday, October 4. The firm has “Buy” rating by Roth Capital given on Friday, May 26. BTIG Research maintained NeoGenomics, Inc. (NASDAQ:NEO) on Friday, May 26 with “Buy” rating. Benchmark initiated it with “Buy” rating and $8 target in Friday, March 11 report. Cantor Fitzgerald initiated the stock with “Overweight” rating in Thursday, December 15 report. The firm earned “Buy” rating on Monday, October 26 by TH Capital. See NeoGenomics, Inc. (NASDAQ:NEO) latest ratings:

26/10/2017 Broker: Janney Capital Rating: Buy
11/09/2017 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Downgrade
24/08/2017 Broker: Gabelli Rating: Buy Initiates Coverage On

Investors sentiment increased to 1.28 in Q3 2017. Its up 0.10, from 1.18 in 2017Q2. It is positive, as 11 investors sold NeoGenomics, Inc. shares while 36 reduced holdings. 21 funds opened positions while 39 raised stakes. 62.50 million shares or 3.94% more from 60.13 million shares in 2017Q2 were reported. Fifth Third Bancorporation holds 0% or 4,000 shares in its portfolio. Raymond James Associate reported 10,485 shares stake. Sei holds 0% in NeoGenomics, Inc. (NASDAQ:NEO) or 37,121 shares. Citadel Advsrs Ltd Liability accumulated 209,520 shares. 11,231 are owned by Ahl Ptnrs Llp. South State Corporation stated it has 0.03% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). 1.12M are held by Emerald Mutual Fund Advisers Trust. Dimensional Fund Advsr Lp owns 0% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 602,806 shares. 2.89M are held by Vanguard Grp Inc. 116,422 were accumulated by Millrace Asset Grp Inc Inc. Ranger Inv Mgmt Lp invested in 0.13% or 153,610 shares. 5,976 are held by Oppenheimer Asset Mgmt. Gsa Capital Partners Llp holds 0.03% or 33,191 shares in its portfolio. First Allied Advisory Services has invested 0.01% in NeoGenomics, Inc. (NASDAQ:NEO). C Worldwide Grp Holding A S reported 0.04% in NeoGenomics, Inc. (NASDAQ:NEO).

The stock increased 9.78% or $0.72 during the last trading session, reaching $8.08. About 794,953 shares traded or 120.29% up from the average. NeoGenomics, Inc. (NASDAQ:NEO) has declined 13.46% since February 21, 2017 and is downtrending. It has underperformed by 30.16% the S&P500.

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company has market cap of $649.71 million. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. It currently has negative earnings. The firm also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clientsÂ’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services.

Among 26 analysts covering Darden Restaurants (NYSE:DRI), 12 have Buy rating, 0 Sell and 14 Hold. Therefore 46% are positive. Darden Restaurants had 97 analyst reports since August 25, 2015 according to SRatingsIntel. Argus Research downgraded the stock to “Hold” rating in Tuesday, October 17 report. Canaccord Genuity maintained Darden Restaurants, Inc. (NYSE:DRI) on Wednesday, September 27 with “Buy” rating. Maxim Group maintained the shares of DRI in report on Tuesday, February 16 with “Buy” rating. The rating was maintained by Robert W. Baird on Wednesday, December 20 with “Buy”. The rating was maintained by Robert W. Baird with “Buy” on Tuesday, January 2. The stock of Darden Restaurants, Inc. (NYSE:DRI) earned “Hold” rating by Jefferies on Monday, September 11. Maxim Group maintained the stock with “Buy” rating in Friday, July 1 report. On Tuesday, June 27 the stock rating was maintained by Canaccord Genuity with “Buy”. The stock has “Hold” rating by Credit Suisse on Wednesday, December 20. The rating was maintained by BMO Capital Markets with “Hold” on Thursday, June 22.

Darden Restaurants, Inc., through its subsidiaries, owns and operates full-service restaurants in the United States and Canada. The company has market cap of $11.84 billion. As of June 27, 2017, it owned and operated approximately 1,700 restaurants under the Olive Garden, LongHorn Steakhouse, Cheddar's Scratch Kitchen, Yard House, The Capital Grille, Seasons 52, Bahama Breeze, and Eddie V's brands. It has a 24.57 P/E ratio.

Since January 10, 2018, it had 0 insider purchases, and 3 selling transactions for $7.25 million activity. $1.05 million worth of stock was sold by Cardenas Ricardo on Wednesday, January 10. The insider Milanes Douglas J. sold 4,300 shares worth $417,315. Another trade for 59,783 shares valued at $5.79 million was made by LEE EUGENE I JR on Wednesday, January 10.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Migdalia James

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts